
[Cancer Research 60, 4838-4844, September 1, 2000]
© 2000 American Association for Cancer Research
Rapid Generation of Potent and Tumor-specific Cytotoxic T Lymphocytes by Interleukin 18 Using Dendritic Cells and Natural Killer Cells1
Fumiaki Tanaka,
Wataru Hashimoto,
Haruki Okamura,
Paul D. Robbins,
Michael T. Lotze and
Hideaki Tahara2
Departments of Surgery [F. T., W. H., M. T. L., H. T.] and Molecular Genetics and Biochemistry [F. T., W. H., P. D. R., M. T. L., H. T.], University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, and Division of Host Defenses, Institution for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan [H. O.]
 |
ABSTRACT
|
|---|
We hypothesized that antitumor-specific immunity, which is induced by
interleukin (IL) 18 treatment in murine tumor models, is promoted by
enhancing natural killer (NK)-mediated destruction of tumor and
delivery to dendritic cells (DCs). These activated and antigen-pulsed
DCs then critically and optimally induce an adoptive immune response,
positioning IL-18 as an important bridge between the innate and
adoptive immune response. The effect of IL-18 added to cultures of live
tumor cells (MCA205, a mouse sarcoma cell line), NK cells, DCs, and T
cells was assessed. When recombinant (r) mIL-18 protein was added to
this culture, potent NK cytolytic activity with subsequent generation
of CTLs was observed in a dose-dependent manner. Without introduction
of either rmIL-18 or NK cells into this culture, systemic cytolytic
activity was significantly decreased. Following the absence of direct
contact of either NK cells or DCs with other cells in this cooperative
coculture system using transwell, the systemic cytolytic activity of
both NK cells and CTLs was greatly suppressed. The cytolysis mediated
by effector cells harvested after completion of the culture was
primarily restricted to MHC class I and highly specific for the tumor
cells used in the coculture. Furthermore, we examined the efficiency in
the induction of cytolytic T cells of other established IFN-
inducing T-cell growth factors, IL-2, and IL-12 in this culture system
and compared them with that mediated by IL-18. Neither IL-2 nor IL-12
induced tumor-specific cytolytic T cells to the same degree as that
mediated by IL-18. Efficacy of this system in induction of
tumor-specific CTLs was also observed in the system using MC38
adenocarcinoma cells. These results are consistent with the notion that
IL-18 induces tumor-specific immunity through enhancing NK activity,
which in turn mediates tumor cell death and activates and primes DCs.
 |
INTRODUCTION
|
|---|
IL3
-18, initially termed "IFN-
-inducing factor," was cloned from
mice with fulminant hepatitis induced by the administration of
Propionibacterium acnes and lipopolysaccharide
(1)
. IL-18 stimulates NK cells, T cells, B cells, and
cells of the monocyte lineage to express IFN-
at high levels
(1
, 2)
. Furthermore, IL-18 plays an important role in
T-cell proliferation (1)
, CTL activation (3)
,
and enhancement of NK cell activity primarily through Fas-FasL
mechanism (2
, 4, 5, 6)
. Systemic administration of rIL-18 is
associated with significant in vivo antitumor effects that
seem to be primarily mediated by enhanced NK activity (7
, 8) . We also have reported that established tumors could be
successfully treated by i.t. injection of recombinant adenoviral
vectors expressing biologically active mIL-18 (Ad.PTH.IL-18; Ref.
9
). Although the mechanism of the antitumor effect has not
been fully explained, we have shown that this antitumor effect is
completely abrogated by depletion of asialo GM-1-positive cells, most
likely NK cells (9)
.
Recent studies, including one using IL-18-deficient mice, support the
notion that IL-18 plays an important role in the development of
cellular immunity (Th1 response) following antigen presentation
(10
, 11) . We have reported that mice treated with i.t.
injection of Ad.PTH.IL-18 rejected a subsequent rechallenge with tumor
cell, suggesting induction of effective tumor immunity with this
treatment (9)
. In the present study, we analyzed the role
of NK cells stimulated with IL-18 in CTL induction against tumor cells
in an in vitro system consisting of live tumor cells, NK
cells, DCs, and T cells with or without rmIL-18. This in
vitro analysis system suggests that NK cells stimulated by IL-18
play a significant role in inducing tumor-specific immunity through
activation and antigen-loading DCs, which are the primary
antigen-presenting cells eliciting an effective adoptive immune
response (12
, 13) .
 |
MATERIALS AND METHODS
|
|---|
Recombinant Cytokines.
Murine rIL-18 was supplied by Hayashibara Biochemical Laboratories
(Okayama, Japan). Murine rIL-4 and murine GM-CSF were generously
provided by Dr. Satwant Narula (Schering-Plough Research Institute,
Kenilworth, NJ). rhIL-2 and rmIL-12 were kindly provided by
Chiron Corp. (Emeryville, CA) and Genetics Institute (Cambridge, MA),
respectively.
Tumor Cell Lines and Animals.
MCA205, a methylcholanthrene-induced murine fibrosarcoma cell line, and
MC38, a murine colon adenocarcinoma, were generous gifts from Dr.
S. A. Rosenberg (National Cancer Institute, Bethesda, MD). The D122
highly metastatic variant of 3LL tumor cells was kindly provided by L.
Eisenbach (Weizmann Institute of Science, Rehovot, Israel). YAC-1 was a
generous gift of W. Chambers (University of Pittsburgh, Pittsburgh,
PA). These cell lines were maintained in RPMI 1640 supplemented with
10% heat-inactivated fetal bovine serum, 2 mM glutamine,
100 mg/ml streptimycin, 100 IU/ml penicillin, and 5 x 10-5 M 2-ME (all from Life Technologies, Inc.,
Grand Island, NY), referred to henceforth as CM. Primary cultures of
syngeneic fibroblasts were obtained from the lungs of C57BL/6 mice
(14)
. Wild-type C57BL/6 mice were purchased from Taconic
Farms (Germantown, NY). The scid/scid C57BL/6 mice were
purchased from The Jackson Laboratory (Bar Harbor, MA). These animals
were maintained in the animal facility at the Center for Biotechnology
and Bioengineering, University of Pittsburgh, and were used for
experiments when they were 712 weeks of age. All of the animals were
ear-tagged, randomized before experiments, and treated and examined in
a blinded fashion.
Cell Preparation.
Bone marrow-derived DCs cultured with GM-CSF and IL-4 for 6 days and
hepatic MNCs and were prepared as described previously, respectively
(14
, 15)
.
Flow Cytometry.
For phenotypic analysis, DCs were stained with PE- or FITC-conjugated
mAbs against murine cell surface molecules (CD11c, CD80, CD86, Gr-1,
H-2Kb, I-Ab, and appropriate isotype controls; all were from
PharMingen, San Diego, CA). Lymphoid cells harvested from lymph nodes
were stained with CD4 and CD8. They were examined with the FACScan
(Becton Dickinson, Sunnyvale, CA).
Cytokine Release or CTLs Assay in Vitro.
To examine the role of NK cells in CTL induction in vitro,
splenocytes from C57BL/6 SCID mice (NK-rich cells) were dissociated in
CM to yield a single-cell suspension. The percentage of NK cells was
determined using mAb (4150%). After erythrocyte lysis, cells of
4 x 105/ml were plated into
24-well plates. Inguinal lymph nodes, abdominal wall lymph nodes, and
axial lymph nodes of naive C57BL/6 mice were collected and suspended in
CM. These cells of 2 x 106/well
were added to NK cells. The percentage of T cells was determined using
antimouse CD8 and antimouse CD4 mAbs (3140% and 3751%,
respectively). Day 6 DCs and tumor cells were resuspended and plated
2 x 105/well and 2 x 104/well, respectively. On day 4, the
number of tumor cells reached 1 x 106. rhIL-2 was added to the culture medium at a
very low final concentration of 25 IU/ml. The rmIL18 was added at
graded doses of 0250 ng/ml in a final volume of 2.4 ml/well. In some
experiments, NK cells were cultured with rIL-18 (250 ng/ml) and rIL-2
(25 IU/ml) for 4 days to analyze the cytolytic activity against MCA205
cells. In some experiments, MCA205 cells were treated with UV at 1.52
mW/cm2 for 30 min and added at 2 x 106/ml (0.5 ml) immediately after
treatment. Forty-eight h after UV treatment, 73% of the MCA205 cells
were confirmed to be apoptotic by Annexin V expression. In some
experiments, either NK cells or DCs were plated in a well using a
0.4-µm pore size transwell (Corning Coster, Cambridge, MA) to prevent
direct cell-to-cell contact. Forty h after the culture, 0.4 ml of
supernatant was collected for ELISA analysis for IFN-
(PharMingen).
The lower detection limit of these assays was 15 pg/ml. For cytotoxic
assay, cells were cultured for 4 days and collected and tested for
cytotoxic activity. Viable lymphoid cells were counted using trypan
blue-exclusion method and used as effector cells for the standard 4-h
51Cr release assay against target cells. In
brief, 106 cells of each target were labeled with
100 µCi of
Na251CrO4
for 1 h, rinsed twice, and plated with target cells at an
appropriate E:T ratio in 96-well round-bottomed plates. The supernatant
(100 µl) was collected after a 4-h incubation, and the radioactivity
was counted with in gamma counter. The percent-specific lysis was
calculated using the following formula: % specific lysis = 100 x (experimental release - spontaneous release)/(maximal release - spontaneous
release). In some experiments, 51Cr release assay
was performed with 50 µl of blocking antibodies against
H-2Kb (HB41/B896) and H-2Kd
(HB159) to examine class I restriction in cell killing [both HB41/B896
and HB159 were kindly provided by E. Gorelik (University of Pittsburgh
Cancer Institute, Pittsburgh, PA)].
Cell Sorting.
After preincubation with antimouse CD32/16 (2.4G2) mAb, liver MNCs were
stained with FITC-conjugated antimouse CD3
(1452C11) and
phycoerythrin-conjugated antimouse NK1.1 (PK136). All mAbs were
obtained from PharMingen. For sorting, a FACS Vantage (Becton Dickinson
Co., San Jose, CA) was used. In experiments to evaluate CTL induction,
sorted NK cells or NKT cells in this way were used in place of
splenocytes harvested from SCID mice as described above.
Statistical Evaluation.
Statistical analysis was performed using a repeated measure ANOVA
method when comparing the in vivo tumor growth and cytotoxic
activity in an individual group. The unpaired two-tailed Students
t test was used to compare cytokine expression. Differences
were considered significant when the P was <0.05.
 |
RESULTS
|
|---|
IL-18 Promotes NK Cell Killing, IFN-
Expression, and Induction
of a Potent and Specific CTL Response in Vitro.
To analyze the NK cell activity enhanced with IL-18, the NK cell
population was cultured with or without IL-18 in the presence of 25
IU/ml rIL-2. As shown in Fig. 1
, the cytolytic activity against MCA205 cells were induced 24 h
after culture in the presence of rIL-18 and gradually reduced
afterward. On day 4, the cytolytic activity of the effector cells
cultured with IL-18 was the same as those without IL-18. These results
indicate that the NK cytolytic activity against MCA205 cells was
rapidly enhanced following stimulation with IL-18.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1. IL-18 stimulates NK cytolytic activity against MCA205
cells. Cells mainly consisting of NK cells (splenocytes from SCID mice)
were cultured with or without 250 ng/ml rIL-18 in the presence of 25
IU/ml IL-2. The cytolytic activity was assessed against MCA205 cells at
an E:T ratio of 20. Data represent the mean ± SD of
cytotoxicity.
|
|
To investigate the role of NK cells in the induction of CTLs by IL-18,
we analyzed cytotoxic activity in a coculture system containing NK
cells, T cells, bone marrow-derived DCs (cultured with GM-CSF and IL-4
for 6 days), and tumor cells. As shown in Figs. 2
3
, tumor cell death was enhanced by the addition of rmIL-18 in a
dose-dependent manner only when both NK cells and IL-18 were included.
Thus, the immediate cytotoxic effect seems to be mediated by NK cells
stimulated with rmIL-18, consistent with the results shown in Fig. 1
,
and was not significantly affected by the presence of T cells or DCs
(Figs. 2
3)
.

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 2. IL-18 enhances NK cytolytic activity and eliminates tumor
cells in an in vitro coculture system. Cocultures
consist of tumor cells, NK cells, DCs, and T cells with various doses
of rmIL-18. On day 3 of coculture, cells were examined and photographed
microscopically. rmIL-18 [250 ng/ml (A), 50 ng/ml
(B), 10 ng/ml (C), and 0 ng/ml
(D)] was added to culture media. Arrows
indicate viable tumor cells. E, growth of MCA205 cells
alone on day 3 using the same number of cells of the coculture. The
original magnification was x200 of each sample.
|
|

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 3. Presence of DCs in tissue culture does not affect
IL-18-induced NK activity. To examine which factors (rmIL-18, NK cells,
DCs, or T cells) are essential for generation of significant NK
activity, effector cells were cocultured under various conditions:
A, IL-18, NK cells, DCs, and T cells; B,
NK cells, DCs, and T cells, (no IL-18); C, IL-18, DCs,
and T cells (no NK cells); D, IL-18, NK cells, and DCs
(no T cells); and E, IL-18, NK cells, and T cells (no
DCs). On day 3 of coculture, culture conditions were examined and
photographed microscopically. Arrows indicate viable
tumor cells. Original magnification, x200.
|
|
The cytotoxicity of CTLs induced in culture containing live MCA205
cells and all of the individual immune cell components with IL-18 was
similar to that obtained from the cultures containing UV-treated MCA205
cells and the immune cell components other than NK cells with rmIL-18.
The cytolytic activity was generated against MCA205 cells, but not
against YAC-1 cells (data not shown). Expression of IFN-
in the
culture was enhanced by rmIL-18 in a dose-dependent manner
(4380 ± 68 pg/ml, 3880 ± 115 pg/ml,
2972 ± 312 pg/ml, and 1097 ± 287 pg/ml
in the presence of rmIL-18 at 250 ng/ml, 50 ng/ml, 10 ng/ml and 0,
respectively). Although the potent CTL activity against MCA205 was
induced in this culture system by rmIL-18 in a dose-dependent fashion,
no cytolytic activity was observed against NK-sensitive YAC-1 cells
(Fig. 4A)
. These findings suggest that IL-18 enhances NK cytolytic
activity, promotes tumor cell destruction, and stimulates IFN-
production in the culture system used.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 4. NK cell killing and subsequent induction of
tumor-specific CTL is augmented by IL-18 at a significant extent when
compared with IL-2 or IL-12 in vitro. A,
cytotoxic activity of effector cells from in vitro
stimulation of cocultures of live tumor cells, NK cells, DCs, and T
cells with various doses of rmIL-18, as shown in Fig. 2
. On day 4 of
coculture, effector cells were collected and cytolytic activity was
assessed against MCA205 cells and YAC-1 cells at various E:T ratios.
Data represent the mean ± SD of cytotoxicity. There is
a statistically significant difference between a group of 250 ng of
IL-18 dose versus that of 10 ng/ml and 0 ng/ml groups,
respectively (P < 0.01).
B, the cytolytic activity against MCA205 cells or YAC-1
cells was examined using effector cells obtained from the coculture
with either IL-2 (1000 IU/ml), IL-12 (1000 pg/ml, 100 pg/ml, or 10
pg/ml), or IL-18 (250 ng/ml). Data represent the mean ± SD of cytotoxicity. Cytolytic activities of effector cells induced with
IL-18 specifically against MCA205 and IL-2 nonspecifically against
YAC-1 are significantly higher than those with other cytokines
(P < 0.05 and P < 0.01, respectively). **, P < 0.01; *, P < 0.05.
|
|
IL-18 Induces Tumor-specific Cytolytic T Cells in this Coculture
More at a Greater Extent than Other IL-2 or IL-12.
To compare the efficiency of IL-18 with other known T-cell growth
factors (IL-2 and IL-12) in inducing cytolytic T cells in
vitro, we tested the same culture systems but with IL-2 (1000
IU/ml), IL-12 (1000 pg/ml, 100 pg/ml, or 10 pg/ml), or IL-18 (250
ng/ml). The cytolytic activity of CTLs generated with IL-18 was the
highest against MCA205 tumor when compared with that induced by IL-2 or
IL-12. The cytolytic activity of CTLs generated with IL-2 was
significantly enhanced against YAC-1 cells but only marginally against
the MCA205 tumor. Use of high-dose IL-12 resulted in significant
elevation of cytolytic activity against MCA205 cells. The level of
cytolytic activity was substantially inferior to that induced by IL-18
(Fig. 4B)
. These results suggest that neither IL-2 nor IL-12
induces tumor-specific cytolytic T cells as efficiently as IL-18 does
in this coculture system under these conditions.
Specific Immunity Is Induced Only When All Components (NK Cells,
DCs, T Cells, and IL-18) Are Present without a Restriction of Direct
Contact among Other Cell Components in this Coculture System.
To examine the role of each individual cell type and cytokine in this
culture system to generate potent CTLs, we examined the activity of
CTLs induced in the culture system lacking an individual component.
Significant CTL activity was induced (P < 0.01 for all others) against MCA205 cells only when all factors were
included in the system (Fig. 5A)
. The cytolytic activity was not generated against YAC-1
cells (data not shown). Furthermore, the cytolytic activity was
abrogated when either NK cells or DCs were separated using the
transwell system, which allowed only the exchange of soluble factors
(Fig. 5B)
. These data indicate that the MCA205-specific CTLs
were induced only when all factors (NK cells, DCs, T cells, and IL-18)
were present in the absence of barrier and in direct contact with each
other.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 5. Specific immunity is induced by this coculture system only
when all components (NK cells, DCs, T cells, and IL-18) were present
without a restriction of direct contact among the cell components.
A, the cytotoxic activity of effector cells was examined
from cocultures containing various components, including live tumor
cells, NK cells, DCs, T cells, and IL-18. On day 4 of coculture,
effector cells were collected and cytolytic activity was assessed
against MCA205 cells at various E:T ratios. Data represent the
mean ± SD of cytotoxicity. There is a statistically
significant difference between the group that contained all components
( ) versus all others lacking an individual element
(**, P < 0.01 for all).
B, effector cells were obtained from coculture
separating either NK cells or DCs using a transwell system as described
in "Materials and Methods." On day 4 of coculture, effector cells
were collected and cytolytic activity was assessed against MCA205 cells
and YAC-1 cells at various E:T ratios. UC, upper chamber
separated cells. Data represent the mean ± SD of
cytotoxicity. There is a statistically significant difference between
the group with no separation and a group with either NK cells or DCs
separated (**, P < 0.01).
|
|
Cytotoxic Activity Is Specific for MCA205 and MHC Class I following
Coculture of NK Cells, DCs, and T Cells with IL-18.
To analyze the specificity of effector cells generated in this system,
the cytolytic activity of effector cells was analyzed against four
different syngeneic cell lines (MCA205, D122, EL-4, and fibroblasts)
and YAC-1 as a NK-sensitive cell line (Fig. 6A)
. Cytotoxicity of the effector cells was significantly
enhanced only against MCA205 cells but not against any other cell lines
(P < 0.01 for all). When the effector cells
were incubated with anti-MHC class I antibody, the cytolytic activity
generated was significantly inhibited (Fig. 6B)
. These
results strongly suggest that cytolytic activity of the effector cells
is MCA205 specific and the recognition of the target cells by the
effector cells is restricted MHC class I manner in this system.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6. Fine specificity of 4-day effector cells is obtained, and
the cytolytic activity is MHC class I restricted in this CCS.
A, cytolytic activity was assessed against MCA205 cells,
D122 cells, EL-4 cells, and YAC-1 cells at various E:T ratios. Data
represent the mean ± SD of cytotoxicity. There is a
statistically significant difference between MCA205 and other targets
(P < 0.01 for all). B,
effector cells were collected from coculture on day 4, and the
cytolytic activity was assessed against MCA205 cells in the presence of
anti-H2Kb antibody or anti-H2Kd antibody, or
without antibody at various E:T ratios. Data represent the
mean ± SD of cytotoxicity. There is a statistically
significant difference between the group following
anti-H2Kb treatment and that of the nontreatment group or
anti-H2Kd treatment group (*: P < 0.05).
|
|
NK Cells, but not NKT Cells, Play the Major Role in Induction of
CTL Activity in This Coculture System.
To analyze the contribution of NK cells and NKT cells in this coculture
system for generating CTLs, sorted NK cells and NKT cells were used.
Using sorted NK cells, the cytolytic activity was greatly enhanced
compared with that with NKT cells (Fig. 7)
. This suggests that NK cells, but not NKT cells, play the central and
important role for induction of CTLs in this coculture system.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7. NK cells, not NKT cells, play an important role in
generating CTLs in this coculture system. T cells were cocultured with
either NK cells or NKT cells with tumor cells and DCs in the presence
of IL-18. After 4 days of coculture, effector cells were collected and
specific cytotoxicity was assessed against MCA205 cells and YAC-1 cells
at various E:T ratios. Data represent the mean ± SD of
cytotoxicity. There is a statistically significant difference between
cocultures containing NK cells and those containing NKT cells (**,
P < 0.01).
|
|
Potent and Specific CTLs Can Be Induced in the System Using Another
Tumor Cell Line, MC38 Adenocarcinoma Cells.
To analyze the efficiency of this coculture system using another cell
line, we tested MC38 murine adenocarcinoma cells in this coculture
system. As shown in Fig. 8, A and B
, the cytolytic activity of CTLs obtained
in this coculture was observed against MC38 cells, but not NK-sensitive
YAC-1 cells. This cytolytic activity was enhanced by rmIL-18 in a
dose-dependent manner. Furthermore, IL-12 or IL-2 failed to generate
CTLs in this coculture at the level achieved with IL-18. These results
support that this approach can be effective for inducing potent CTLs
against weakly immunogenic tumors. Only modest cytolytic activity was
induced for the B16 melanoma (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 8. Tumor-specific cytolytic activity is generated against
another murine tumor (MC38 adenocarcinoma) in an IL-18 dose-dependent
manner at a greater degree than IL-2 or IL-12. A, cells
were cocultured for 4 days. When MC38 adenocarcinoma cells were
involved in this coculture system with various doses of IL-18, the
cytolytic activity was assessed against MC38 and YAC-1 cells at various
E:T ratios. Data represent the mean ± SD of
cytotoxicity. There is a statistically significant difference between
the group using 250 ng of IL-18 versus those of the 50,
10, and 0 ng/ml groups (**, P < 0.01).
B, the cytolytic activity of effector against MC38 cells
or YAC-1 cells was examined using effector cells obtained from the
coculture cells consisting of MC38 cells, NK cells, DCs, T cells, and
25 IU/ml IL-2 with either IL-2 (1000 IU/ml), IL-12 (1000 pg/), IL-18
(250 ng/ml), or no extra cytokine. Data represent the mean ± SD of cytotoxicity. Cytolytic activities of effector cells
induced with IL-18 against MC38 is significantly higher than those with
other cytokines (P < 0.01).
|
|
 |
DISCUSSION
|
|---|
Attempts to develop T-cell culture systems with outgrowth of
specific T cells to tumor have been carried out for 20 years since the
first identification of T-cell growth factor, now called IL-2
(16)
. Problems related to these attempts initially
ascribed to contamination with mitogens or lack of nominal T-cell
effectors (17)
subsequently turned to those associated
with use of concentrations of IL-2 that were sufficient to maintain
nonspecific T cells with lymphokine-activated killer cell-like activity
(18)
. Although the addition of IL-4 (19)
,
IL-7 (20)
, IL-10 (21)
, or IL-12
(22)
to cultures could either decrease
lymphokine-activated killer cell-like activity or increase expansion,
simple strategies did not allow rapid selection of specific T cells,
and many groups turned to use of complex feeder systems, purposeful use
of mitogens, or early cloning strategies. Here, we explored the use of
DCs coupled with activated NK and näive T cells in conjunction
with IL-18 to derive specific effector cells to tumor. This was
developed based on the observation of potent and specific tumor
responses induced by i.t. injection of adenoviral vector-expressing
IL-18.
We have previously reported that i.t. injection of adenovirus
vector-expressing IL-18 induces specific immunity but depletion of
asialo GM1-positive cells, primarily NK cells, which
substantially abrogate the IL-18-mediated antitumor effects.
Considering these findings, we hypothesized that tumor-specific
immunity could be efficiently promoted by first inducing tumor cell
destruction by NK cells stimulated with IL-18. To examine the role of
IL-18 in inducing specific immunity, we used an in vitro CCS
containing viable tumor cells, NK cells, DCs, and T cells as well as
cytokines, including IL-18, IL-2, or IL-12. The results of this CCS
suggest that IL-18 enhances NK activity, inducing death of viable tumor
cells that in turn seem to be acquired and processed by DCs to promote
CTL generation from näive T cells. As shown in Figs. 1
2
3
, tumor
cells were destroyed by NK cells activated with IL-18, and
tumor-specific CTLs were induced as an apparent consequence. This
NK-mediated destruction of tumor cells was enhanced by the presence of
IL-18 in a dose-dependent manner (Fig. 2
, AE). As a
result, the specific cytolytic activity of CTLs against MCA205
fibrosarcoma cells was augmented by the presence of IL-18 in a
dose-dependent manner (Fig. 4A)
. As shown in Fig. 1
, NK
cells after coculture of 96 h exhibited marginal cytolytic
activity against tumor cells involved in the coculture. Thus, the
effector cells that showed cytolytic effect against tumor cells after
coculture were considered to be CTL effectors. Similar findings were
also observed when MC38 adenocarcinoma cells were used in the system
(Fig. 8A)
. These findings, indeed, suggest that tumor cell
destruction by NK cells is an important initiating event for inducing
tumor-specific CTLs.
To investigate the role of the individual components involved in this
system for generating MCA205-specific CTLs, we examined a CCS lacking
individual components. As shown in Fig. 3
, AE, MCA205
cells were completely killed only when both rmIL-18 and NK cells were
present during culture. Presence of DCs in culture did not alter the
extent of MCA205 death and relevant lymphocyte proliferation. However,
the most potent and specific cytolytic activity was observed only when
the culture contained all components, including IL-18, NK cells, DCs,
and T cells. When any of the factors were missing in the culture, the
cytolytic activity was significantly reduced (P < 0.01 for all; Fig. 5A
). To analyze the role of the
direct contact of NK cells with tumor cells, we performed the CCS using
transwells, separating NK cells and their targets. As shown in Fig. 5B
, the cytolytic activity was greatly reduced when direct
contact was inhibited between NK cells and other cells components.
These results would indicate that the presence of NK cells play an
important role in inducing specific immunity against tumor cells.
To determine the role of NK and NKT cells in CCS for efficient and
rapid CTL induction, we sorted NK cells and NKT cells from liver MNCs.
As shown in Fig. 7
, potent cytolytic activity of the effector cells was
induced when NK cells were included in the CCS, but not when NKT cells
were used. Some reports have shown the results consistent with our
data. Local production of IFN-
by NK cells, but not NKT cells, was
shown to be important for generating xenospecific CTLs
(23)
. Leite-de-Moraes et al.
(24)
also demonstrated that NKT cells could kill the Fas+
cells following stimulation with IL-18 and IL-12, but cannot do with
IL-18 alone. Thus, it seems that NK cells, but not NKT cells, play an
important role in supplying antigen to DCs by mediating tumor cell
death.
Furthermore, we examined the efficiency of other established and
IFN-
inducing T-cell growth factors, IL-2 and IL-12, and compared
them with IL-18 in the induction of cytolytic T cells against MCA205
fibrosarcoma cells and MC38 adenocarcinoma cells, respectively. The
expression of IFN-
including either IL-12 or IL-18 in the coculture
is 4869 pg/ml and 3315 pg/ml (when cocultured with MCA205) and 4844
pg/ml and 3751 pg/ml (when cocultured with MC38), respectively. These
data showed that the difference of the effect of IL-12 and IL-18 for
induction of IFN-
was considered to be marginal. These results
suggest that neither IL-2 nor IL-12 induces tumor-specific cytolytic T
cells as IL-18 does in this CCS (Figs. 4B
and 8B)
. Effective and rapid generation of such potent cytolytic
activity against tumor cells, and potentially other targets, could be
quite useful for development of adoptive immunotherapies as well as for
generation of T cells important for antigen identification.
DCs play an important role as primary antigen-presenting cells to
initiate and maintain T-cell responses. We and others have shown that
DCs pulsed with tumor-associated antigens (25, 26, 27)
, tumor
lysates (28)
, or RNA (29
, 30)
allow selection
and/or activation of specific CTLs. DCs present exogeneous antigens on
MHC class I molecules to induce priming or tolerance of CD8+ cells
(31)
. As a source of the antigens, DCs phagocyte apoptotic
cells to provide antigenic peptides and necrotic cells to be matured
(32)
. In this study, we have demonstrated that DCs are an
important cell population in generating effective CTLs against tumor in
combination with IL-18 and NK cells in this CCS (Fig. 5)
. As shown in a
previous study (33)
, we have demonstrated here that CTL
induction against tumor cells was suppressed when DCs were absent (Fig. 5A)
or separated (Fig. 5B)
in the coculture well.
At the beginning of the coculture, the day 6 DC showed 85% of MHC
class II, 81% of CD80, 81% of CD86, and 68% of CD11c. Our data have
demonstrated that CD11c, CD80, and CD86 expression of DCs after
coculture with apoptotic cells or without coculture was not altered
within 48 h from the coculture, thereafter increased when
cocultured with apoptotic cells (34)
. Although the
addition of rmIL-18 does not directly affect surface markers of DCs
(data not shown), DC functions are affected by contact with tumor
cells. We have recently identified dynamic changes in chemokine
receptor expression (up-regulation of CCR7) on DCs following contact
with apoptotic tumor (34)
. Also, we demonstrated in this
study that effective CTLs were not generated when DCs were separated in
the coculture using transwell, showing that direct contact with other
elements in the coculture could be important for generating CTLs. Taken
together, IL-18 seems to induce more frequent and effective tumor cell
death through enhancing NK activity, enabling, in turn, DCs to serve as
effective antigen-presenting cells, and then inducing potent and
specific immunity. Thus, the implications are that IL-18/NK/DC plays a
critical inductive and interactive role in promoting tumor-specific
immunity. Furthermore, such T cells might be useful to be used in the
clinic for adoptive immunotherapy and the research for identification
of novel tumor associated antigens.
 |
ACKNOWLEDGMENTS
|
|---|
We thank Susan F. Schoonover for excellent technical assistance.
We are grateful to Masashi Kurimoto (Hayashibara Biochemical
Laboratories, Inc., Okayama, Japan) for providing rmIL-18 and to Dr. A.
Donnenberg (University of Pittsburgh, Pittsburgh, PA) for help with
cell-sorting study.
 |
FOOTNOTES
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by NIH Grant PO1-CA59371 (to
M. T. L., P. D. R., and H. T.), a Career Development Award from
the American Society of Clinical Oncology (to H. T.), and The Uehara
Memorial Foundation (Tokyo, Japan) Postdoctoral Research Fellowship (to
F. T.). 
2 To whom requests for reprints should be
addressed, at Department of Surgery and Bioengineering, The Institute
of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai,
Minato-ku, Tokyo, 108-8639, Japan. Phone: 81-3-5449-5345; Fax:
81-3-5449-5444; E-mail: tahara{at}ims.u-tokyo.ac.jp 
3 The abbreviations used are: IL, interleukin; NK,
natural killer; DC, dendritic cell; i.t., intratumoral; CM, complete
medium; MNC, mononuclear cell; CCS, cooperative coculture system;
GM-CSF, granulocyte machrophage-colony-stimulating factor; r,
recombinant; mAb, monoclonal antibody. 
Received 1/ 4/00.
Accepted 7/ 5/00.
 |
REFERENCES
|
|---|
-
Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., Torigoe K., Okura T., Nukada Y., Hattori K., Akita K., Namba M., Tanabe F., Konishi K., Fukuda S., Kurimoto M. Cloning of a new cytokine that induces IFN-
production by T cells. Nature (Lond.), 378: 88-91, 1995.[Medline]
-
Okamura H., Nagata K., Komatsu T., Tanimoto T., Nukata Y., Tanabe F., Akita K., Torigoe K., Okura T., Fukuda S., Kurimoto M. A novel costimulatory factor for
interferon induction found in the livers of mice causes endotoxic shock. Infect. Immun., 63: 3966-3972, 1995.[Abstract]
-
Okamoto I., Kohno K., Tanimoto T., Ikegami H., Kurimoto M. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. J. Immunol., 162: 3202-3211, 1999.[Abstract/Free Full Text]
-
Dao T., Mehal W. Z., Crispe I. N. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J. Immunol., 161: 2217-2222, 1998.[Abstract/Free Full Text]
-
Hashimoto W., Osaki T., Okamura H., Robbins P. D., Kurimoto M., Nagata S., Lotze M. T., Tahara H. Differential antitumor effects of administration of rIL-18 or rIL-12 are mediated primarily by Fas-Fas Ligand- and perforin-induced tumor apoptosis, respectively. J. Immunol., 163: 583-589, 1999.[Abstract/Free Full Text]
-
Ushio S., Namba M., Okura T., Hattori K., Nukada Y., Akita K., Tanabe F., Konishi K., Micallef M., Fujii M., Torigoe K., Tanimoto T., Fukuda S., Ikeda M., Okamura H., Kurimoto M. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J. Immunol., 156: 4274-4279, 1996.[Abstract]
-
Osaki T., Peron J. M., Cai Q., Okamura H., Robbins P. D., Kurimoto M., Lotze M. T., Tahara H. IFN-
-inducing factor/IL-18 administration mediates IFN-
- and IL-12-independent antitumor effects. J. Immunol., 160: 1742-1749, 1998.[Abstract/Free Full Text]
-
Micallef M. J., Yoshida K., Kawai S., Hanaya T., Kohno K., Arai S., Tanimoto T., Torigoe K., Fujii M., Ikeda M., Kurimoto M. In vivo antitumor effects of murine interferon-
-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother., 43: 361-367, 1997.[Medline]
-
Osaki T., Hashimoto W., Gambotto A., Okamura H., Robbins P. D., Kurimoto M., Lotze M. T., Tahara H. Potent antitumor effects mediated by local expression of the mature form of the interferon-
inducing factor, interleukin-18 (IL-18). Gene Ther., 6: 808-815, 1999.[Medline]
-
Takeda K., Tsutsui H., Yoshimoto T., Adachi O., Yoshida N., Kishimoto T., Okamura H., Nakanishi K., Akira S. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity, 8: 383-390, 1998.[Medline]
-
Robinson D., Shibuya K., Mui A., Zonin F., Murphy E., Sana T., Hartley S. B., Menon S., Kastelein R., Bazan F., OGarra A. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-
production and activates IRAK and NF
B. Immunity, 7: 571-581, 1997.[Medline]
-
Steinman R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.[Medline]
-
Macatonia S. E., Taylor P. M., Knight S. C., Askonas B. A. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J. Exp. Med., 169: 1255-1264, 1989.[Abstract/Free Full Text]
-
Nishioka Y., Hirao M., Robbins P. D., Lotze M. T., Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res., 59: 4035-4041, 1999.[Abstract/Free Full Text]
-
Goossens P. L., Jouin H., Marchai G., Milon G. Isolation and flow cytometric analysis of the free lymphomyeloid cells present in murine liver. J. Immunol. Methods, 132: 137-144, 1990.[Medline]
-
Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro of T lymphocytes from normal human bone marrows. Science (Washington DC), 193: 1007-1008, 1976.[Abstract/Free Full Text]
-
Lotze M. T., Strausser J. L., Rosenberg S. A. In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. J. Immunol., 124: 2972-2978, 1980.[Abstract]
-
Lotze M. T., Rosenberg S. A. In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. J. Immunol., 126: 2215-2220, 1981.[Abstract]
-
Kawakami Y., Rosenberg S. A., Lotze M. T. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med., 168: 2183-2191, 1988.[Abstract/Free Full Text]
-
Welch P. A., Namen A. E., Goodwin R. G., Armitage R., Cooper M. D. Human IL-7: a novel T cell growth factor. J. Immunol., 143: 3562-3567, 1989.[Abstract]
-
MacNeil I. A., Suda T., Moore K. W., Mosmann T. R., Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J. Immunol., 145: 4167-4173, 1990.[Abstract]
-
Zeh, H. J., 3rd, Hurd, S., Storkus, W. J., and Lotze, M. T. Interleukin-12 promotes the ploriferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J. Immunother. 14: 155161, 1993.
-
Smyth M. J., Kelly J. M. Accessory function for NK1. 1+ natural killer cells producing interferon-gamma in xenospecific cytotoxic T lymphocyte differention. Transplantation (Baltimore), 68: 840-843, 1999.
-
Leite-de-Moraes M., Hameg A., Arnould A., Machavoine F., Koezuka Y., Schneider E., Herbelin A., Dy M. A distinct IL-18-induced pathway to fully activate NKT lymphocytes independently from TCR engagement. J. Immunol., 163: 5871-5876, 1999.[Abstract/Free Full Text]
-
Mayordomo J. I., Zorina T., Storkus W. J., Zitvogel L., Celluzzi C., Falo L. D., Melief C. J., Ildstad S. T., Kast W. M., Deleo A. B., Lotze M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.[Medline]
-
Zitvogel L., Mayordomo J. I., Tjandrawan T., DeLeo A. B., Clarke M. R., Lotze M. T., Storkus W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.[Abstract/Free Full Text]
-
Porgador A., Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med., 182: 255-260, 1995.[Abstract/Free Full Text]
-
Flamand V., Sornasse T., Thielemans K., Demanet C., Bakkus M., Bazin H., Tielemans F., Leo O., Urbain J., Moser M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol., 24: 605-610, 1994.[Medline]
-
Ashley D. M., Faiola B., Nair S., Hale L. P., Bigner D. D., Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med., 186: 1177-1182, 1997.[Abstract/Free Full Text]
-
Boczkowski D., Nair S. K., Synder D., Gilboa E. Dentritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med., 184: 465-472, 1996.[Abstract/Free Full Text]
-
Wick M. J., Ljunggren H. G. Processing of bacterial antigens for peptide presentation on MHC class I molecules. Immunol. Rev., 172: 153-162, 1999.[Medline]
-
Sauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S., and Bhardwaj, N. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med., 191: 423434, 2000.
-
Fernandez N. C., Lozier A., Flament C., Ricciardi-Castangnoli P., Bellet D., Perricaudet M., Tursz T., Maraskovsky E., Zitovogel L. Dendritic cells directly trigger NK cells function: cross-talk relevant in innate anti-tumor responses in vivo. Nat. Med., 5: 405-411, 1999.[Medline]
-
Hirao M., Onai N., Hiroishi K., Watkins S. C., Matushima K., Robbins P. D., Lotze M. T., Tahara H. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res., 60: 2209-2217, 2000.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS
J. Leukoc. Biol.,
July 1, 2008;
84(1):
1 - 26.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination
J. Leukoc. Biol.,
July 1, 2008;
84(1):
27 - 49.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Robertson, J. W. Mier, T. Logan, M. Atkins, H. Koon, K. M. Koch, S. Kathman, L. N. Pandite, C. Oei, L. C. Kirby, et al.
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Clin. Cancer Res.,
July 15, 2006;
12(14):
4265 - 4273.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh
Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin.
Cancer Res.,
May 1, 2006;
66(9):
4913 - 4921.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ahmad and F. Alvarez
Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis
J. Leukoc. Biol.,
October 1, 2004;
76(4):
743 - 759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ribas, J. A. Wargo, B. Comin-Anduix, S. Sanetti, L. Y. Schumacher, C. McLean, V. B. Dissette, J. A. Glaspy, W. H. McBride, L. H. Butterfield, et al.
Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells
J. Immunol.,
April 15, 2004;
172(8):
4762 - 4769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Massa, C. Guiducci, I. Arioli, M. Parenza, M. P. Colombo, and C. Melani
Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable hsp70
Cancer Res.,
February 15, 2004;
64(4):
1502 - 1508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Mashino, N. Sadanaga, F. Tanaka, M. Ohta, H. Yamaguchi, and M. Mori
Effective Strategy of Dendritic Cell-based Immunotherapy for Advanced Tumor-bearing Hosts: the Critical Role of Th1-dominant Immunity
Mol. Cancer Ther.,
August 1, 2002;
1(10):
785 - 794.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Veenstra, Z. L. Jonak, S. Trulli, and J. A. Gollob
IL-12 Induces Monocyte IL-18 Binding Protein Expression Via IFN-{gamma}
J. Immunol.,
March 1, 2002;
168(5):
2282 - 2287.
[Abstract]
[Full Text]
[PDF]
|
 |
|